Clinical Trial Update: A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of Tegavivint (BC2059) in patients with advanced hepatocellular carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Tegavivint (BC2059) (Tegavivint)

Snippet

Sponsor: Iterion Therapeutics | Conditions: Advanced Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: RECRUITING